ArticleMedicine2026
Identification and validation of mitochondrial metabolism-ralated biomarkers in coronary heart disease.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary heart disease (CHD) affects life quality of patients by impaired coronary artery blood supply. We were planning to study the molecular mechanisms of mitochondrial metabolism-related genes (MMRGs) in CHD. The following data were sourced from public databases: transcriptome data of CHD and MMRGs. The candidate genes were obtained by differential expression analysis and MMRGs. The identification of biomarkers was facilitated by machine learning algorithms and gene expression analyses. Of particular significance was the utilization of the nomogram for the evaluation of the diagnostic efficacy of the biomarkers. Following this, enrichment analysis, immune infiltration analysis, compound prediction and molecular docking were performed. Expression levels of biomarkers were tested in vitro by reverse transcription quantitative polymerase chain reaction (RT-qPCR). Palmitoyl protein thioesterase 2 (PPT2) and Mediator complex subunit21(MED21) were validated as biomarkers. A nomogram developed utilizing these biomarkers demonstrated a satisfactory capacity for differentiating among various sample types. The neuroactive ligand-receptor interaction, polycomb repressive complex, protein processing in endoplasmic reticulum, and calcium signaling pathway were the pathway co-enriched by biomarkers. Immune infiltration analysis indicated that PPT2 and MED21 were anticorrelated with regulatory T cells and central memory CD4 T cells, respectively. In addition, 20 compounds targeting PPT2 and MED21 were identified, respectively. Notably, molecular docking studies demonstrated a strong binding affinity between PPT2 and benzo(a)pyrene. The RT-qPCR analyses confirmed the downregulation of PPT2 and MED21 in CHD. PPT2 and MED21 were identified associated with mitochondrial metabolism in CHD, providing effective support for clinical diagnosis of CHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.